Labiotech.eu

News and Trends 19 Oct 2022

Report says 20% of global cancer deaths could be avoided

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

October 19, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Domain Therapeutics to start clinical trials of solid tumor treatment

Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Nucleome Therapeutics raises £37.5M to deliver precision medicines

U.K. biotech company Nucleome Therapeutics Limited has closed an oversubscribed £37.5 million ($42.4 million) series A financing round. The funds will be used to advance the company’s autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The financing was led by new investor M Ventures, the strategic, corporate […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

Best in Biotech 18 Oct 2022

The hottest private biotech companies in Australia

Australia has a strong base in biotechnology, with many incentives for R&D and commercialization. Here are the top five private Australian biotech companies that have recently showcased the country’s credentials in the sector. Australia is a highly developed nation in the Southern Hemisphere. Famous for its huge wool trade and iron ore wealth, the country […]

October 18, 2022 - 5 minutesmins - By Jonathan Smith

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

EditForce creates U-to-C RNA-editing technology

EditForce, Inc., headquartered in Fukuoka, Japan, has created the world’s first RNA-editing technology that enables RNA-editing bases to be changed from U (uracil) to C (cytosine). The RNA editing company also demonstrated that technology works in human cells in a joint study with Takahiro Nakamura, Faculty of Agriculture, Kyushu University. The researchers said the study […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Emergex develops vaccine for smallpox and monkeypox

Emergex Vaccines Holding Limited has formulated and confirmed the synthesis and assembly of a CD8+ T cell adaptive vaccine for smallpox and monkeypox, made up predominantly of early “eclipse phase” antigens. The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share […]

October 18, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Progress of COPD drug boosted by debt financing of up to $150M

Verona Pharma plc has today (October 17) announced that it has entered into a debt financing facility providing access of up to $150 million from Oxford Finance LLC. The non-dilutive capital provides further financial flexibility and support for commercialization activities for ensifentrine, the company’s product candidate, which recently reported positive phase 3 data in the […]

October 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Gene activity could help identify risk of kidney cancer spreading

Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet (KI) in Sweden in a preclinical study published in Nature Communications. “This could potentially […]

October 17, 2022 - 4 minutesmins - By Jim Cornall

More News! 17 Oct 2022

Clinical trial of treatment for advanced solid tumors approved

A clinical trial of a drug to treat advanced solid tumors has been approved by the National Medical Products Administration. China-based Akeso Inc., made the announcement on Sunday (October 16) about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific […]

October 17, 2022 - 2 minutesmins - By Liza Laws

In Depth 17 Oct 2022

UK grants that can give biotech startups a vital jump-start

Grants are a vital lifeline that help biotech startups get off the ground, especially for underrepresented entrepreneurs. The Women in Synthetic Biology (WiSB) network recently gave detailed advice for helping U.K. biotech founders access this funding. Women are a big source of talent in the biotech space, both in academic life sciences and in founding […]

October 17, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 17 Oct 2022

Ophthalmology biopharma company Oculis combines with EBAC

Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named Oculis Holding SA and will work to accelerate the development […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Report says 20% of global cancer deaths could be avoided

Domain Therapeutics to start clinical trials of solid tumor treatment

Nucleome Therapeutics raises £37.5M to deliver precision medicines

The hottest private biotech companies in Australia

Empyrean Neuroscience launches with $22M to target CNS disorders

EditForce creates U-to-C RNA-editing technology

Emergex develops vaccine for smallpox and monkeypox

Progress of COPD drug boosted by debt financing of up to $150M

Gene activity could help identify risk of kidney cancer spreading

Clinical trial of treatment for advanced solid tumors approved

UK grants that can give biotech startups a vital jump-start

Ophthalmology biopharma company Oculis combines with EBAC

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!